ProMIS Neurosciences (PMN) Price & Analysis

Compare

178 Followers

PMN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.38 - $1.59

Previous CloseN/A

Volume32.49K

Average Volume (3M)14.63M

Market Cap

$29.27M

Enterprise Value$12.32M

Total Cash (Recent Filing)$4.54M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Nov 12, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding51,806,496

10 Day Avg. Volume843,030

30 Day Avg. Volume14,633,773

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.42

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.46

Forecast

1Y Price Target

$5.00

Price Target Upside825.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

FDA Approval ProcessThe FDA has granted Fast Track designation to PMN310, potentially accelerating its approval process for treating Alzheimer's disease.

Market OpportunityThe Alzheimer's market presents a massive commercial opportunity, with a potential market exceeding $10 billion annually for an effective anti-amyloid antibody without ARIA risk.

Safety ProfilePMN310 shows no binding to amyloid plaque, unlike rival antibodies, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA).

Bears Say

Dependency On Future DataThe upcoming first-in-patient P1b data in 2026 is a key catalyst and potential proof-of-concept for PMN310.

Funding ConcernsPipeline seems interesting, but funding is an issue.

ProMIS Neurosciences News

ProMIS Neurosciences files $50M mixed securities shelf

16:38 EDT ProMIS Neurosciences (PMN) files $50M mixed securities shelf Published first on TheFly – the ultimate source...

10d ago

PMN

ProMIS Neurosciences reports Q2 EPS (29c) vs (13c) last year

“The team’s exceptional focus and execution in the first half of 2025 culminated in what has been an...

11d ago

PMN

ProMIS Neurosciences to present overview from PRECISE-AD trial

ProMIS Neurosciences (PMN) announced it has been invited to present an overview of its ongoing PRECISE-AD trial in...

26d ago

PMN

ProMIS Neurosciences announces private placement financing

ProMIS Neurosciences (PMN) entered into a purchase agreement with existing institutional and accredited investors to issue and sell...

27d ago

PMN

ProMIS Neurosciences Announces At The Market Offering

ProMIS Neurosciences ( ($PMN) ) has issued an announcement. On August 13, 2025, ProMIS Neurosciences Inc. announced an...

4d ago

PMN

ProMIS Neurosciences: Advancements in Alzheimer’s Treatment and Strong Financial Positioning Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on ProMIS Neurosciences, with a price target of...

9d ago

PMN

ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss

ProMIS Neurosciences Inc. ( ($PMN) ) has released its Q2 earnings. Here is a breakdown of the information...

10d ago

PMN

ProMIS Neurosciences Announces $3M PIPE Offering

ProMIS Neurosciences ( ($PMN) ) has shared an update. On July 28, 2025, ProMIS Neurosciences announced a private...

27d ago

PMN

ProMIS Neurosciences Announces $3.2M Fundraising Initiatives

An announcement from ProMIS Neurosciences ( ($PMN) ) is now available. On July 22, 2025, ProMIS Neurosciences announced...

1M ago

PMN

ProMIS Neurosciences announces $0.8M registered direct offering

ProMIS Neurosciences (PMN) has raised $0.8M at-the-market from an existing healthcare focused institutional investor. The company has entered...

1M ago

PMN

ProMIS Neurosciences announces private placement financing

ProMIS Neurosciences (PMN) entered into a purchase agreement with an existing institutional and accredited investor to issue and...

1M ago

PMN

ProMIS Neurosciences Gains FDA Fast Track for PMN310

The latest announcement is out from ProMIS Neurosciences ( ($PMN) ). On July 21, 2025, ProMIS Neurosciences announced...

1M ago

PMN

3 Penny Stocks to Watch Now, 7/22/25

reAlpha Tech Corp., ProMIS Neurosciences, and Incannex Healthcare Ltd. are the 3 Penny Stocks to watch on July 22, 2025,...

1M ago

PMN

AIRE

Buy Rating for ProMIS Neurosciences Driven by Fast Track Designation and Promising Alzheimer’s Treatment Potential

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ProMIS Neurosciences and keeping the price target...

1M ago

PMN

PMN FAQ

What was ProMIS Neurosciences’s price range in the past 12 months?

ProMIS Neurosciences lowest stock price was $0.38 and its highest was $1.59 in the past 12 months.

What is ProMIS Neurosciences’s market cap?

ProMIS Neurosciences’s market cap is $29.27M.

When is ProMIS Neurosciences’s upcoming earnings report date?

ProMIS Neurosciences’s upcoming earnings report date is Nov 12, 2025 which is in 80 days.

How were ProMIS Neurosciences’s earnings last quarter?

ProMIS Neurosciences released its earnings results on Aug 13, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.174 by -$0.116.

Is ProMIS Neurosciences overvalued?

According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ProMIS Neurosciences pay dividends?

ProMIS Neurosciences does not currently pay dividends.

What is ProMIS Neurosciences’s EPS estimate?

ProMIS Neurosciences’s EPS estimate is -0.24.

How many shares outstanding does ProMIS Neurosciences have?

ProMIS Neurosciences has 51,806,496 shares outstanding.

What happened to ProMIS Neurosciences’s price movement after its last earnings report?

ProMIS Neurosciences reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.174. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of ProMIS Neurosciences?

Currently, no hedge funds are holding shares in PMN

ProMIS Neurosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-19.56%

Trailing 12-Months

Asset Growth

574.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ProMIS Neurosciences

ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.

ProMIS Neurosciences (PMN) Earnings & Revenues

Historic Earnings Reports

PMN Stock 12 Month Forecast

Average Price Target

$5.00

▲(825.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,1.3261538461538462,1.8823076923076925,2.4384615384615387,2.994615384615385,3.550769230769231,4.106923076923078,4.663076923076924,5.219230769230769,5.775384615384615,6.331538461538463,6.8876923076923084,7.443846153846154,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,1.0953846153846154,1.4207692307692308,1.7461538461538464,2.071538461538462,2.396923076923077,2.7223076923076928,3.047692307692308,3.3730769230769235,3.698461538461539,4.023846153846154,4.34923076923077,4.674615384615386,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.9415384615384615,1.113076923076923,1.2846153846153845,1.4561538461538461,1.6276923076923078,1.7992307692307692,1.9707692307692306,2.1423076923076922,2.313846153846154,2.485384615384615,2.6569230769230767,2.8284615384615384,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.1,"date":1575158400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1585699200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >